


## PHARMACEUTICAL 2017



## BIOSPECIFICS TECHNOLOGIES CORP Rank 1 of 292





## PHARMACEUTICAL 2017



## BIOSPECIFICS TECHNOLOGIES CORP Rank 1 of 292

The relative strengths and weaknesses of BIOSPECIFICS TECHNOLOGIES CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of BIOSPECIFICS TECHNOLOGIES CORP compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 113% points. The greatest weakness of BIOSPECIFICS TECHNOLOGIES CORP is the variable Assets, Current, reducing the Economic Capital Ratio by 6.7% points.

The company's Economic Capital Ratio, given in the ranking table, is 358%, being 355% points above the market average of 2.9%.

| Input Variable                              | Value in<br>1000 USD |
|---|----------------------|
| Assets, Current                             | 55,400               |
| Cost of Goods Sold                          | 0                    |
| Intangible Assets                           | 258                  |
| Liabilities, Current                        | 1,997                |
| Liabilities, Non-Current                    | 0                    |
| Other Assets                                | 9,038                |
| Other Compr. Net Income                     | 0                    |
| Other Expenses                              | 6,003                |
| Other Liabilities                           | 0                    |
| Other Net Income                            | 349                  |
| Other Revenues                              | 26,251               |
| Property and Equipment                      | 0                    |
| Research and Development                    | 1,328                |
| Selling, General and Administrative Expense | 7,897                |

| Output Variable          | Value in<br>1000 USD |
|--------------------------|----------------------|
| Assets                   | 64,696               |
| Liabilities              | 1,997                |
| Expenses                 | 15,227               |
| Revenues                 | 26,251               |
| Stockholders Equity      | 62,700               |
| Net Income               | 11,372               |
| Comprehensive Net Income | 11,372               |
| Economic Capital Ratio   | 358%                 |

